Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OT-1602
- Development stage
- Preclinical
- Lead developer
- Ocumension Biotech
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Ophthalmic
01
Overview
OT-1602 is an investigational stem cell therapy being developed by Ocumension Therapeutics for the treatment of optic neuritis. The therapy is designed to promote the repair and regeneration of the optic nerve, which is typically damaged by inflammation or demyelination in patients with this condition. By leveraging the regenerative potential of stem cells, OT-1602 aims to restore visual function and provide neuroprotection for the optic nerve fibers. It represents Ocumension's expansion into advanced cell-based therapies for posterior eye diseases and is currently in the early stages of development within the company's ophthalmic pipeline.
Beyond the preview
Go deeper on OT-1602.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OT-1602.